---
schema_version: "secwatch.filing_event.v1"
accession: "0000816956-26-000051"
form_type: "8-K"
ticker: "CNMD"
cik: "0000816956"
company_name: "CONMED Corp"
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T02:35:41.020591+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CONMED Q1 2026: GAAP EPS $0.45, adjusted EPS $0.89; raises FY organic revenue growth guidance

## Summary
- Sales $317.0M (-1.3% YoY); domestic -5.8%, international +4.7% as reported.
- GAAP EPS $0.45 vs $0.19 YoY; adjusted EPS $0.89 vs $0.95.
- FY 2026 organic constant currency revenue growth guidance raised to 5.0-6.5% from 4.5-6.0%.
- Reported revenue guidance raised to $1.350-1.375B; adjusted EPS reaffirmed $4.30-$4.45.
- GI product exit impacted sales by $15.5M; company focusing on higher-growth areas.

## SEC filing metadata
- accession: 0000816956-26-000051
- form_type: 8-K
- ticker: CNMD
- cik: 0000816956
- company_name: CONMED Corp
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/816956/000081695626000051/0000816956-26-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/816956/000081695626000051/cnmd-20260429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000816956-26-000051
- JSON: https://secwatch.observer/filing/0000816956-26-000051.json
- Plain text: https://secwatch.observer/filing/0000816956-26-000051.txt

## Key facts
- Earnings Releases
  CONMED Corp reported FY 2026 results: EPS $4.30 to $4.45. Guidance reaffirmed.
  - Period: FY 2026
  - EPS: $4.30 to $4.45
  - Guidance: reaffirmed
  - Result: guidance update
  source text: The Company now expects year-over-year organic constant currency revenue growth, which excludes gastroenterology product sales, of approximately 5.0% to 6.5% compared to the prior guidance range of 4.5% to 6.0%. Full-year 2026 reported revenue is now expected to be in the range of $1.350 billion to $1.375 billion, compared to prior guidance of $1.345 billion to $1.375 billion.
  evidence_url: https://www.sec.gov/Archives/edgar/data/816956/000081695626000051/0000816956-26-000051-index.htm
- Earnings Releases
  CONMED Corp reported FY 2026 results: EPS $4.30 to $4.45. Guidance reaffirmed.
  - Period: FY 2026
  - EPS: $4.30 to $4.45
  - Guidance: reaffirmed
  - Result: guidance update
  source text: The Company continues to expect full-year adjusted diluted net earnings per share (2) in the range of $4.30 to $4.45.
  evidence_url: https://www.sec.gov/Archives/edgar/data/816956/000081695626000051/0000816956-26-000051-index.htm
- Earnings Releases
  CONMED Corp reported Q1 2026 results: EPS $0.89.
  - Period: Q1 2026
  - EPS: $0.89
  - Result: reported results
  source text: Adjusted diluted net earnings per share (1) were $0.89, compared to adjusted diluted net earnings per share of $0.95 in the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/816956/000081695626000051/0000816956-26-000051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.